Additional file 2 of Association of genetic variants related to combined lipid-lowering and antihypertensive therapies with risk of cardiovascular disease: 2 × 2 factorial Mendelian randomization analyses
Creators: name: Li, Ying
name: Liu, Hongwei
name: Shen, Chong
name: Li, Jianxin
name: Liu, Fangchao
name: Huang, Keyong
name: Gu, Dongfeng
name: Li, Yun
name: Lu, Xiangfeng
Publisher: name: figshare
Year: 2024
Subjects: subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: Pharmacology
subject: Biotechnology
subject: Virology
subject: Computational Biology

description: Additional file 2: Fig. S1. Participant flow chart of the study in the UK Biobank. Fig. S2. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of ischemic stroke. Fig. S3. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of hemorrhagic stroke. Fig. S4. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of heart failure. Fig. S5. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of diabetes mellitus. Fig. S6. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of chronic kidney disease. Fig. S7. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of dementia. Fig. S8. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of peripheral artery diseases. Fig. S9. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of cardiovascular diseases, with additional adjustment for body mass index. Fig. S10. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of coronary artery diseases, with additional adjustment for body mass index. Fig. S11. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of stroke, with additional adjustment for body mass index. Fig. S12. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of cardiovascular disease, as defined by a kinship coefficient of 0.0442. Fig. S13. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of coronary artery disease, as defined by a kinship coefficient of 0.0442. Fig. S14. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of stroke, as defined by a kinship coefficient of 0.0442. Fig. S15. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of cardiovascular disease, using 30th percentiles and 70th percentile for grouping. Fig. S16. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of coronary artery disease, using 30th percentiles and 70th percentile for grouping. Fig. S17. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of stroke, using 30th percentiles and 70th percentile for grouping. Fig. S18. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of cardiovascular diseases, with eQTL as the genetic proxies for these four drugs. Fig. S19. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of coronary artery disease, with eQTL as the genetic proxies for these four drugs. Fig. S20. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of stroke, with eQTL as the genetic proxies for these four drugs. Fig. S21. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of cardiovascular disease, excluding participants who used lipid-lowering or antihypertensive drugs at baseline. Fig. S22. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of coronary artery disease, excluding participants who used lipid-lowering or antihypertensive drugs at baseline. Fig. S23. Associations of exposure to genetically proxied lipid-lowering drugs, genetically proxied antihypertensive drugs, or both with risk of stroke, excluding participants who used lipid-lowering or antihypertensive drugs at baseline.